Physician profile
Paul Sacks
NPI 1255334892
$7,917.85
in general payments reported to CMS, 2019-2025
33 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $514 · 2021: $458 · 2022: $979 · 2023: $1,615 · 2024: $2,328 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,299 · Education: $55.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.69 |
| Education | $55.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,542.89 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $714.17 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $664.94 | 2021-2025 | |
| Amgen INC. | $653.63 | 2022-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $470.61 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $376.45 | 2022-2025 | |
| Ardelyx, INC. | $368.86 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Opko Pharmaceuticals, LLC | $308.90 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $300.41 | 2019-2025 | Veltassa, Korsuva |
| W. L. Gore & Associates, INC. | $285.28 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $224.34 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.89 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $209.71 | 2019-2024 | Ultomiris |
| Daiichi Sankyo INC. | $186.80 | 2021-2025 | Injectafer |
| Akebia Therapeutics INC | $163.02 | 2019-2025 | Auryxia, Vafseo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $160.18 | 2021-2023 | Krystexxa |
| Nevro Corp. | $146.71 | 2024 | Senza |
| Baxter Healthcare | $127.51 | 2024 | |
| Novartis Pharmaceuticals Corporation | $125.46 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $110.80 | 2023-2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $89.70 | 2021-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $74.57 | 2019-2024 | |
| Novo Nordisk INC | $66.67 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $61.10 | 2024 | Amvuttra, Oxlumo |
| Aurinia Pharma U.S., INC. | $51.40 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.38 | 2019 | |
| Boston Scientific Corporation | $44.39 | 2023-2024 | |
| Cormedix INC. | $42.13 | 2025 | Defencath |
| Gilead Sciences, INC. | $20.73 | 2023 | Veklury |
| Lilly USA, LLC | $19.32 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $19.05 | 2019 | |
| Genentech USA, INC. | $12.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.